Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients

Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients

  • Post published:September 8, 2021
  • Post category:Press Release
Read more about the article Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

Danish And British Startups Partner to Bring Innovative Psychedelics to Patients

  • Post published:September 8, 2021
  • Post category:Press Release
Read more about the article Octarine Bio announces the expansion of its Scientific Advisory Board

Octarine Bio announces the expansion of its Scientific Advisory Board

  • Post published:July 19, 2021
  • Post category:Press Release
Read more about the article Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

  • Post published:March 11, 2021
  • Post category:Press Release
Read more about the article Nick Milne, Co-founder and CSO at Octarine Bio

Nick Milne, Co-founder and CSO at Octarine Bio

  • Post published:November 19, 2020
  • Post category:Interview
Read more about the article European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives

European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives

  • Post published:November 12, 2020
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More